1783 / 1851
Endpoint
STAR-01
ACCORD
12/0405
CAO/ARO/
AIO-04
NSABP
R-04
PETACC-6
PCR
16%
both
arms
14%
vs
19%
12.8%
vs
16.5%
(p=0.038)
19% vs
21%
11.5%
vs
13%
CRM
4%
vs
7%
8%
vs
13%
5%
vs 6% No
data
2%
vs 2%
Node +
(stage
III)
29%
vs
26%
30%
vs
26%
27%
vs
26%
Not
stated
27%
vs
26%
Oxaliplatin Phase III trials:
Control arm in red